EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
MAR 2023
TABLES
123
PAGES
196
EDITION
6
PRICE
USD 4950
CODE
MCP13899
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global PEGylated Proteins Market to Reach $1.8 Billion by 2030
In the changed post COVID-19 business landscape, the global market for PEGylated Proteins estimated at US$889.7 Million in the year 2022, is projected to reach a revised size of US$1.8 Billion by 2030, growing at aCAGR of 9.2% over the period 2022-2030. Consumables, one of the segments analyzed in the report, is projected to record 8.6% CAGR and reach US$1.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Services segment is readjusted to a revised 10.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $264.5 Million, While China is Forecast to Grow at 8.5% CAGR
The PEGylated Proteins market in the U.S. is estimated at US$264.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.
SELECT PLAYERS
BIA Separations d.o.o.; Biomatrik Inc.; Celares GmbH; Creative PEGWorks; IRIS Biotech GmbH; Jenkem Technology Co., Ltd.; Thermo Fisher Scientific, Inc.
SEGMENTS
» Product (Consumables, Services) » Protein Type (Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII, Other Protein Types) » End-Use (Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutes)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
PEGylated Proteins – Global Key Competitors Percentage Market Share in 2020 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2020 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World PEGylated Proteins Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
JAPAN |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
CHINA |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
EUROPE |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
FRANCE |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
GERMANY |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
UNITED KINGDOM |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
ASIA-PACIFIC |
PEGylated Proteins Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for PEGylated Proteins by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic Research Institutes for the Years 2023 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com